cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.qd9rge
title: Occurrence Download

description: A dataset containing 2495 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Ecsenius bicolor"
 ]
}

 The dataset includes 2495 records from 76 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014330-250802193616735/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29827778
title: <b>Giardia duodenalis</b><b> </b><b>MIF induces </b><b>host</b><b> </b><b>intestinal damage via CD74</b><b> </b><b>receptor</b><b> </b><b>mediated NLRP3 inflammasome activation</b>

description: Duodenum is an important zoonotic protozoan that primarily causes diarrhea and has a significant negative impact on global public health. There are very few Enterobacteria. Infiguration and adaptive immune response of macrophage migration inhibitory factor (MIF) as an inflammatory mediator, the role of duodenal macrophage migration inhibitory factor (GdMIF) in host injury is now studied to induce CD74-NF-κB-NLRP3 inflammasome activation of GdMIF in vitro and in vivo and its effect on intestinal injury in the duodenum in study. We found that GdMIF is an exocrine protein with dopamine tautomerase activity. GdMIF activates eNF-κB and NLRP3 inflammasomes, increases the release of eGSDMD-NT fragments and lactate dehydrogenase (LDH), and promotes the production of e-pro-inflammatory cytokines. Interaction CD74 molecule Co-IP and BiFC validation. In addition, low CD74 and NF-κB significantly inhibit the production of pro-inflammatory cytokines in macrophages. Gerbils infected with duodenum blocked by GdMIF had lower NLRP3 expression and milder intestinal damage than Denal birch. Inhibition of NLRP3 may reduce Enterobacter denites infection In summary, GdMIF induces NLRP3 inflammasome activation and pyroptosis by interacting with CD74 receptors, which in turn triggers a pro-inflammatory response and leads to intestinal damage.
DOI: 10.6084/m9.figshare.29827778.v1
title: <b>Giardia duodenalis</b><b> </b><b>MIF induces </b><b>host</b><b> </b><b>intestinal damage via CD74</b><b> </b><b>receptor</b><b> </b><b>mediated NLRP3 inflammasome activation</b>

description: Duodenum is an important zoonotic protozoan that primarily causes diarrhea and has a significant negative impact on global public health. There are very few Enterobacteria. Infiguration and adaptive immune response of macrophage migration inhibitory factor (MIF) as an inflammatory mediator, the role of duodenal macrophage migration inhibitory factor (GdMIF) in host injury is now studied to induce CD74-NF-κB-NLRP3 inflammasome activation of GdMIF in vitro and in vivo and its effect on intestinal injury in the duodenum in study. We found that GdMIF is an exocrine protein with dopamine tautomerase activity. GdMIF activates eNF-κB and NLRP3 inflammasomes, increases the release of eGSDMD-NT fragments and lactate dehydrogenase (LDH), and promotes the production of e-pro-inflammatory cytokines. Interaction CD74 molecule Co-IP and BiFC validation. In addition, low CD74 and NF-κB significantly inhibit the production of pro-inflammatory cytokines in macrophages. Gerbils infected with duodenum blocked by GdMIF had lower NLRP3 expression and milder intestinal damage than Denal birch. Inhibition of NLRP3 may reduce Enterobacter denites infection In summary, GdMIF induces NLRP3 inflammasome activation and pyroptosis by interacting with CD74 receptors, which in turn triggers a pro-inflammatory response and leads to intestinal damage.
DOI: 10.15468/dl.xp7zvf
title: Occurrence Download

description: A dataset containing 633 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Motacilla samveasnae)",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "License is one of (CC-BY 4.0, CC0 1.0)"
 ]
}

 The dataset includes 633 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014332-250802193616735/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29827895.v1
title: Supplementary Material for: Direct Hemoperfusion with Polymethylmethacrylate for Hemodialysis Patients with Dialysis-related Amyloidosis

description: Introduction
Dialysis-related amyloidosis (DRA) is a serious complication in patients undergoing long-term dialysis that leads to conditions such as carpal tunnel syndrome and destructive spondyloarthropathy. Improved removal of the precursor protein β2-microglobulin (β2-m) is considered an effective treatment strategy for DRA. Polymethylmethacrylate (PMMA) membranes have the capacity to adsorb β2-m in dialysis filters, suggesting that direct hemoperfusion with PMMA in addition to standard dialysis may enhance β2-m removal.
Methods
This prospective cohort study included 10 patients undergoing hemodialysis, who were diagnosed with DRA. The participants were treated with dialysis filter alone during Visit 1, both standard dialysis filter and PMMA cartridges (FT-75, volume 75 cm³) during Visits 2–4, and FT-145 PMMA cartridges (volume 145 cm³) during Visits 5–7. The removal rates and clearances of β2-m were quantified. We also assessed the removal of α1-microglobulin (α1-m), matrix metalloproteinase-3 (MMP-3), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-α), which may be associated with DRA symptoms. 
Results
PMMA cartridge had increased β2-m removal rates compared to dialysis filter alone for treatment duration of 240 min. Similarly, the removal rates of α1-m and MMP-3 were higher with PMMA cartridges than with dialysis filter alone. β2-m, α1-m, and MMP-3 clearance improved with the addition of PMMA cartridges, depending on the cartridge size. The removal rates of IL-6 and TNF-α were higher with PMMA cartridges than with dialysis filter alone at 30 min, but not at 240 min .
Conclusion
Direct hemoperfusion with PMMA is an effective method for removing β2-m in hemodialysis patients with DRA. Beneficial effects were also observed for the removal of α1-m and MMP-3. Further research is required to evaluate the long-term efficacy of this approach in managing DRA.
DOI: 10.6084/m9.figshare.29827895
title: Supplementary Material for: Direct Hemoperfusion with Polymethylmethacrylate for Hemodialysis Patients with Dialysis-related Amyloidosis

description: Introduction
Dialysis-related amyloidosis (DRA) is a serious complication in patients undergoing long-term dialysis that leads to conditions such as carpal tunnel syndrome and destructive spondyloarthropathy. Improved removal of the precursor protein β2-microglobulin (β2-m) is considered an effective treatment strategy for DRA. Polymethylmethacrylate (PMMA) membranes have the capacity to adsorb β2-m in dialysis filters, suggesting that direct hemoperfusion with PMMA in addition to standard dialysis may enhance β2-m removal.
Methods
This prospective cohort study included 10 patients undergoing hemodialysis, who were diagnosed with DRA. The participants were treated with dialysis filter alone during Visit 1, both standard dialysis filter and PMMA cartridges (FT-75, volume 75 cm³) during Visits 2–4, and FT-145 PMMA cartridges (volume 145 cm³) during Visits 5–7. The removal rates and clearances of β2-m were quantified. We also assessed the removal of α1-microglobulin (α1-m), matrix metalloproteinase-3 (MMP-3), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-α), which may be associated with DRA symptoms. 
Results
PMMA cartridge had increased β2-m removal rates compared to dialysis filter alone for treatment duration of 240 min. Similarly, the removal rates of α1-m and MMP-3 were higher with PMMA cartridges than with dialysis filter alone. β2-m, α1-m, and MMP-3 clearance improved with the addition of PMMA cartridges, depending on the cartridge size. The removal rates of IL-6 and TNF-α were higher with PMMA cartridges than with dialysis filter alone at 30 min, but not at 240 min .
Conclusion
Direct hemoperfusion with PMMA is an effective method for removing β2-m in hemodialysis patients with DRA. Beneficial effects were also observed for the removal of α1-m and MMP-3. Further research is required to evaluate the long-term efficacy of this approach in managing DRA.
DOI: 10.6084/m9.figshare.29827898
title: Supplementary Material for: Pansclerotic morphea, refractory to multiple systemic therapies, successfully treated with UVA-1 phototherapy

description: Introduction: 
Pansclerotic morphea is a rare and debilitating variant of localized scleroderma characterized by extensive skin sclerosis. Conventional therapies may be ineffective, particularly in patients with comorbidities that limit treatment options, prompting the need for alternative modalities. 

Case Presentation: 
A 29-year-old African American male with autoimmune hepatitis presented with progressive sclerotic plaques on the trunk and extremities, accompanied by nonhealing leg ulcers. Biopsy and clinical findings confirmed pansclerotic morphea. Prior treatments, including topical and systemic corticosteroids, were unsuccessful, and methotrexate was contraindicated. Given the refractory nature of the disease, UVA-1 phototherapy was initiated as salvage therapy. 

Conclusion: 
After six months of UVA-1 phototherapy, the patient showed marked clinical improvement, including softening of skin induration and complete wound healing, with no adverse effects. This case underscores the value of UVA-1 phototherapy as a safe and effective treatment for severe morphea, especially in patients unable to receive standard immunosuppressive therapies.
DOI: 10.6084/m9.figshare.29827898.v1
title: Supplementary Material for: Pansclerotic morphea, refractory to multiple systemic therapies, successfully treated with UVA-1 phototherapy

description: Introduction: 
Pansclerotic morphea is a rare and debilitating variant of localized scleroderma characterized by extensive skin sclerosis. Conventional therapies may be ineffective, particularly in patients with comorbidities that limit treatment options, prompting the need for alternative modalities. 

Case Presentation: 
A 29-year-old African American male with autoimmune hepatitis presented with progressive sclerotic plaques on the trunk and extremities, accompanied by nonhealing leg ulcers. Biopsy and clinical findings confirmed pansclerotic morphea. Prior treatments, including topical and systemic corticosteroids, were unsuccessful, and methotrexate was contraindicated. Given the refractory nature of the disease, UVA-1 phototherapy was initiated as salvage therapy. 

Conclusion: 
After six months of UVA-1 phototherapy, the patient showed marked clinical improvement, including softening of skin induration and complete wound healing, with no adverse effects. This case underscores the value of UVA-1 phototherapy as a safe and effective treatment for severe morphea, especially in patients unable to receive standard immunosuppressive therapies.
DOI: 10.6084/m9.figshare.29827901
title: Supplementary Material for: Trajectory of hematoma growth and functional recovery after intracerebral hemorrhage: a latent class analysis of BASC data

description: Background: Moderate blood pressure (BP) reduction reduces hematoma growth but this has not been shown to translate into improved functional recovery after intracerebral hemorrhage (ICH). This study aims to define patient profiles according to hematoma growth and functional recovery patterns, and explore the prognostic factors of the patterns.
Methods: Analysis of the Blood pressure in Acute Stroke Collaboration (BASC) dataset involving randomized controlled trials of early BP lowering in acute ICH. Latent class analysis was used to identify patient profiles by hematoma volume change from baseline to 24 hours on outcomes trajectories. Clinical outcomes include functional outcomes measured according to modified Rankin Scale (mRS) and serious adverse events at follow-up (usually 90 days). Generalized linear mixed models were used with adjustment of source trial as a random effect for clustering to identify the prognostic factors. 
Results: Among 6221 participants from BASC, 2450 patients (mean age 64.1+13.1 years, female 36.7%) were included. Baseline hematoma volumes (ml) were 6.8, 13.2, 27.1 and 59.2, respectively, for each class identified by patient profiles: no growth with favorable outcome (52.1%, median growth 0.2 [IQR -0.4 to 1.1] ml, median mRS 2 [IQR 1-2]), mild growth with disability (32.6%, 0.8 [-0.8 to 4.6] ml, mRS 4 [4-5]), moderate growth with death or disability (13.2%, 11.2 [4.9 to 27.0] ml, mRS 4 [3-6]) and large growth with death (2.1%, 35.2 [12.8 to 81.2] ml, mRS 6 [6-6]). Patients with moderate growth were younger and more likely to undergo neurosurgery neurosurgery than those in the mild or large growth groups. Baseline hematoma volume was the only significant factor associated with all the hematoma pattern groups. 
Conclusions: Patients with moderate growth were younger and more likely to receive neurosurgery than those in the mild or large growth groups. Baseline hematoma volume is the most important factor for hematoma growth and clinical outcome.
DOI: 10.6084/m9.figshare.29827901.v1
title: Supplementary Material for: Trajectory of hematoma growth and functional recovery after intracerebral hemorrhage: a latent class analysis of BASC data

description: Background: Moderate blood pressure (BP) reduction reduces hematoma growth but this has not been shown to translate into improved functional recovery after intracerebral hemorrhage (ICH). This study aims to define patient profiles according to hematoma growth and functional recovery patterns, and explore the prognostic factors of the patterns.
Methods: Analysis of the Blood pressure in Acute Stroke Collaboration (BASC) dataset involving randomized controlled trials of early BP lowering in acute ICH. Latent class analysis was used to identify patient profiles by hematoma volume change from baseline to 24 hours on outcomes trajectories. Clinical outcomes include functional outcomes measured according to modified Rankin Scale (mRS) and serious adverse events at follow-up (usually 90 days). Generalized linear mixed models were used with adjustment of source trial as a random effect for clustering to identify the prognostic factors. 
Results: Among 6221 participants from BASC, 2450 patients (mean age 64.1+13.1 years, female 36.7%) were included. Baseline hematoma volumes (ml) were 6.8, 13.2, 27.1 and 59.2, respectively, for each class identified by patient profiles: no growth with favorable outcome (52.1%, median growth 0.2 [IQR -0.4 to 1.1] ml, median mRS 2 [IQR 1-2]), mild growth with disability (32.6%, 0.8 [-0.8 to 4.6] ml, mRS 4 [4-5]), moderate growth with death or disability (13.2%, 11.2 [4.9 to 27.0] ml, mRS 4 [3-6]) and large growth with death (2.1%, 35.2 [12.8 to 81.2] ml, mRS 6 [6-6]). Patients with moderate growth were younger and more likely to undergo neurosurgery neurosurgery than those in the mild or large growth groups. Baseline hematoma volume was the only significant factor associated with all the hematoma pattern groups. 
Conclusions: Patients with moderate growth were younger and more likely to receive neurosurgery than those in the mild or large growth groups. Baseline hematoma volume is the most important factor for hematoma growth and clinical outcome.
DOI: 10.6084/m9.figshare.29827904
title: Supplementary Material for: Influence of multiple long-term conditions on outcome after thrombolysis for acute ischemic stroke: secondary analysis of the ENCHANTED trial

description: Background: The influence of multiple long-term conditions on the outcomes from acute ischemic stroke (AIS) are not well defined. This study aimed to determine the association of multiple long-term conditions in participants of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).
Methods: ENCHANTED was an international, multicenter, 2 x 2 quasi-factorial, open, randomised controlled, blinded endpoint assessed, trial that assessed the effectiveness and safety of intensive blood pressure lowering and low-dose thrombolysis against standard of care in adults with AIS. Multiple long-term condition was defined as two or more coexisting chronic conditions according to medical history. The primary outcome was function recovery (distribution of scores on the modified Rankin scale) and mortality at 90 days post-randomization. Associations were estimated in multivariate logistic regression models and an assessment of heterogeneity was undertaken in subgroups included age, sex, baseline systolic blood pressure, and clinical features.
Results: In 4,566 AIS participants (mean age 66.7 years, 37.8% female), those with multiple long-term conditions were older, more often female, and had more severe neurological impairment. Multiple long-term conditions increased the odds of poor functional outcome (adjusted odds ratio [aOR] 1.16, 95% confidence interval [CI] 1.03-1.30; p=0.020) and mortality (aOR 1.35, 95% CI 1.04-1.76; p=0.024). The association between multiple long-term conditions and mortality/functional outcome were consistent across all subgroups.
Conclusions: Individuals with multiple long-term conditions have higher odds of poor functional outcome and death after thrombolytic treatment for AIS.
Clinical Trial Registration: The trial is registered at ClinicalTrials.gov (NCT01422616)
URL: clinicaltrials.gov/study/NCT01422616
DOI: 10.6084/m9.figshare.29827904.v1
title: Supplementary Material for: Influence of multiple long-term conditions on outcome after thrombolysis for acute ischemic stroke: secondary analysis of the ENCHANTED trial

description: Background: The influence of multiple long-term conditions on the outcomes from acute ischemic stroke (AIS) are not well defined. This study aimed to determine the association of multiple long-term conditions in participants of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).
Methods: ENCHANTED was an international, multicenter, 2 x 2 quasi-factorial, open, randomised controlled, blinded endpoint assessed, trial that assessed the effectiveness and safety of intensive blood pressure lowering and low-dose thrombolysis against standard of care in adults with AIS. Multiple long-term condition was defined as two or more coexisting chronic conditions according to medical history. The primary outcome was function recovery (distribution of scores on the modified Rankin scale) and mortality at 90 days post-randomization. Associations were estimated in multivariate logistic regression models and an assessment of heterogeneity was undertaken in subgroups included age, sex, baseline systolic blood pressure, and clinical features.
Results: In 4,566 AIS participants (mean age 66.7 years, 37.8% female), those with multiple long-term conditions were older, more often female, and had more severe neurological impairment. Multiple long-term conditions increased the odds of poor functional outcome (adjusted odds ratio [aOR] 1.16, 95% confidence interval [CI] 1.03-1.30; p=0.020) and mortality (aOR 1.35, 95% CI 1.04-1.76; p=0.024). The association between multiple long-term conditions and mortality/functional outcome were consistent across all subgroups.
Conclusions: Individuals with multiple long-term conditions have higher odds of poor functional outcome and death after thrombolytic treatment for AIS.
Clinical Trial Registration: The trial is registered at ClinicalTrials.gov (NCT01422616)
URL: clinicaltrials.gov/study/NCT01422616
DOI: 10.6084/m9.figshare.29827907
title: Supplementary Material for: Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study

description: Introduction: The potential for curative conversion with immunotherapy-based systemic treatment used with noncurative intent in patients with hepatocellular carcinoma (HCC) remains debated. This study aimed to provide a reliable epidemiological snapshot of response patterns to Atezolizumab plus Bevacizumab (AB) therapy, with a focus on curative conversion rates. 
Methods: Patients with HCC undergoing first-line noncurative AB or Lenvatinib (LENV, used as reference) from 2019 to 2023 were included, using centre-level aggregate data from a broad international consortium. The primary endpoint was the curative conversion rate, differentiating potential conversion (PC) - when objective response (OR) resulted in a consistent decrease in tumour burden and alpha-fetoprotein levels - from actual conversion (AC), when OR led to curative treatment. Secondary endpoints included OR, under-conversion (UC; [PC - AC]/OR) rates, and crude survival rates of AC patients. A meta-analytic approach was employed to analyse aggregate data. 
Results: Forty-eight international centres treating 2,379 patients with HCC with a noncurative intent (1,401 with AB and 978 with LENV) were included. A significant discrepancy was observed between PC (16% and 13% for AB and LENV, p=0.03) and AC rates (3% for both AB and LENV, p=0.14). 
UC rates remained similarly high (40% and 36% for AB and LENV, p=0.93), despite differing OR rates (29% and 24% for AB and LENV, p=0.01). Subgroup and meta-regression analyses did not identify any clear treatment, centre, or patient patterns that explained the high UC rate. The 3-year survival rate for the 72 patients who underwent a curative conversion after AB was 93%. 
Conclusions: Although patients treated with AB achieved higher OR and PC rates than those treated with LENV, AC remained similarly low, highlighting a potentially worrisome UC phenomenon in real life, also with novel immunotherapy-based combinations.
DOI: 10.15468/dl.dn2tu4
title: Occurrence Download

description: A dataset containing 191 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Moupinia poecilotis)",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "License is one of (CC-BY 4.0, CC0 1.0)"
 ]
}

 The dataset includes 191 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014333-250802193616735/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.